Review Article
The Epidemiology of COVID-19 Vaccine-Induced Myocarditis
Table 2
Overview of the baseline characteristics of the studies.
| Reference | Publication year | Country | Type of study | Mean age (years) | Sample size | Follow-up (days) | Male (% total) | mRNA vaccine type | Number of myocarditis cases | Male (% myocarditis) | Myocarditis diagnostics | Number of hospitalizations | Number of deaths |
| El Sahly et al. [49] | 2021 | USA | Population study | 51 | 14287 | 14 | 53 | Moderna | 0 | 0 | N/A | 0 | 0 | Walter et al. [50] | 2022 | Population study | 8 | 1518 | 7 | 52 | Pfizer | 0 | 0 | N/A | 0 | 0 | Simone et al. [51] | 2021 | Population study | 49 | 2392924 | 10 | 46 | Pfizer/Moderna | 15 | 100 | Clinical | 0 | 0 | Ali et al. [52] | 2021 | Population study | 14 | 2489 | 83 | 52 | Moderna | 1 | 0 | N/A | 0 | 0 | Diaz et al. [53] | 2022 | Population study | 57 | 2000287 | N/A | 41 | Pfizer/Moderna | 20 | 75 | Abnormal troponin or CMR evidence | 19 | 0 | Montgomery et al. [54] | 2021 | Population study | 25 | 2810000 | N/A | 100 | Pfizer/Moderna | 23 | 100 | Clinical | 0 | 0 |
| Le Vu et al. [55] | 2022 | France | Population study | 28 | 18129 | 30 | 61 | Pfizer/Moderna | 82 | 79 | Hospital admission codes | N/A | N/A |
| Husby et al. [56] | 2022 | Denmark | Population study | N/A | 3482295 | 28 | N/A | Pfizer | 48 | 73 | Clinical diagnosis + troponin elevation + hospitalization >24 hours | 28 | 1 | Population study | N/A | 498814 | 28 | N/A | Moderna | 21 | N/A | Clinical diagnosis + troponin elevation + hospitalization >24 hours | 8 | 0 |
| Patone et al. [57] | 2022 | UK | Population study | 56 | 16993389 | 28 | 33 | Pfizer | 158 | 67 | Hospital admission codes | N/A | N/A | Population study | 40 | 1006191 | 28 | 26 | Moderna | 9 | 83 | Hospital admission codes | N/A | N/A |
| Witberg et al. [58] | 2021 | Israel | Population study | 44 | 2500000 | 42 | 49 | Pfizer | 54 | 94 | Clinical | 1 | 1 | Mevorach et al. [59] | 2021 | Population study | 33 | 5000000 | 30 | 49 | Pfizer | 136 | 91 | Clinical | 114 | 1 | Barda et al. [46] | 2021 | Population study | 38 | 884828 | 42 | 52 | Pfizer | 21 | 91 | Clinical | N/A | N/A |
|
|